

Characteristic	All patients n=288 (%)	mAbs only treated patients n=94	Antivirals only treated patients n=171	mAbs and antivirals treated patients n=23
Gender n (%)				
Male	151 (52.4%)	50 (53.2%)	87 (50.9%)	14 (60.9%)
Female	137 (47.6%)	44 (46.8%)	84 (49.1%)	9 (39.1%)
Age				
Mean (SD)	63.6 ($\pm$ 16.1)	67 ($\pm$ 15.1)	62.4 ($\pm$ 16.5)	58.3 ($\pm$ 15.8)
65 years or older n (%)	158 (54.9%)	59 (62.8%)	91 (53.2%)	8 (34.8%)
Mean BMI (SD)	28.3 ($\pm$ 6.1)	29.2 ($\pm$ 6.6)	27.8 ($\pm$ 5.7)	27.8 ($\pm$ 5.8)
Comorbidities n (%)				
Cardiac insufficiency	14 (4.9%)	4 (4.3%)	8 (4.7%)	2 (8.7%)
Cerebral ischemia history	28 (10.9%)	13 (13.8%)	13 (7.6%)	2 (8.7%)
COPD	53 (18.4%)	13 (13.8%)	37 (21.6%)	3 (13%)
Autoimmune diseases	36 (12.5%)	7 (7.4%)	25 (14.6%)	4 (17.4%)
Vasculopathy	24 (8.3%)	12 (12.8%)	9 (5.3%)	3 (13%)
Hepatic cirrhosis	6 (2.1%)	1 (1.1%)	5 (2.9%)	0
Obesity	91 (31.6%)	35 (37.2%)	51 (29.8%)	5 (21.7%)
Diabetes				
Compensated disease	63 (21.9%)	24 (25.5%)	36 (21.1%)	3 (13%)
Decompensated disease	10 (3.5%)	3 (3.2%)	6 (3.5%)	1 (4.3%)
Chronic kidney diseases	19 (6.6%)	9 (9.6%)	7 (4.1%)	3 (13%)
Solid cancer				
Localized disease	34 (11.8%)	6 (6.4%)	23 (13.5%)	5 (21.7%)
Metastatic disease	15 (5.2%)	3 (3.2%)	12 (7.1%)	0

Hematological malignancies	43 (14.9%)	10 (10.6%)	23 (13.5%)	10 (43.5%)
AIDS	1 (0.3%)	1 (1.1%)	0	0
History of peptic ulcer	2 (0.7%)	0	2 (1.2%)	0
Ischemic heart diseases	36 (12.5%)	15 (16%)	17 (9.9%)	4 (17.4%)
Dementia	17 (5.9%)	10 (10.6%)	7 (4.1%)	0
Hemiplegia	3 (1%)	1 (1.1%)	1 (0.6%)	1 (4.3%)
Hypertension	165 (57.3%)	60 (63.8%)	93 (54.4%)	12 (52.2%)
Number of comorbidities ≥ 3	113 (39.2%)	44 (46.8%)	60 (35.1%)	9 (39.1%)
Charlson Comorbidity Index (mean $\pm$ SD)	4.1 ($\pm$ 2.3)	4.2 ($\pm$ 2.2)	4 ($\pm$ 2.3)	4.1 ($\pm$ 2.2)
Vaccination				
Yes	232 (82.3%)	56 (59.6%)	161 (94.2%)	18 (78.3%)
No	51 (17.7%)	38 (40.4%)	10 (5.8%)	5 (21.7%)
Mean days from symptoms onset to first positive swab (SD)	1.3 (1.4)	1.7 (1.7)	1.2 (1.2)	1.1 (1.1)
Mean days from symptoms onset to treatment (SD)	3.3 (1.9)	3.9 (2.4)	3.1 (1.5)	3.5 (2.2)
Baseline clinical severity n (%)				
ASY	47 (16.3%)	39 (41.5%)	3 (1.8%)	5 (21.7%)
MID	235 (81.6%)	52 (55.3%)	167 (97.6%)	16 (69.6%)
MOD	6 (2.1%)	3 (3.2%)	1 (0.6%)	2 (8.7%)
IgG anti-SARS-CoV-2-Spike protein at baseline n (%)				
Positive	70 (24.3%)	45 (47.9%)	18 (10.5%)	7 (30.4%)
Negative	65 (22.6%)	46 (48.9%)	4 (2.3%)	15 (65.2%)
N/A	153 (53.1%)	3 (3.2%)	149 (87.1%)	1 (4.3%)
Monoclonal antibodies n (%)*				
Bamlanivimab/Etesevimab	42 (35.9%)	40 (42.6%)	-	2 (8.7%)

Casirivimab/Imdevimab	22 (18.8%)	17 (18.1%)	-	5 (21.7%)
Sotrovimab	53 (45.3%)	37 (39.4%)	-	16 (69.6%)
**Total number	117	94	-	23
Antivirals n (%)*				
Remdesivir	57 (29.1%)	-	38 (22.2%)	18 (78.3%)
Molnupiravir	77 (39.8%)	-	75 (43.9%)	2 (8.7%)
Nirmatrelvir/Ritonavir	61 (31.1%)	-	58 (33.9%)	3 (13%)
**Total number	195	-	171	23
COVID-19 progression and related hospital admission				
Yes	4 (1.4%)	3 (3.2%)	1 (0.6%)	0
No	284 (98.6%)	91 (96.8%)	170 (99.4%)	23 (100%)

Table 1: socio-demographic, co-morbidities, clinical characteristics, prescribed therapies and outcome of SARS-CoV-2-infected patients.

Legend to table 1: SD, standard deviation; COPD, chronic obstructive pulmonary disease; ASY, asymptomatic or pre-symptomatic; MID, mild; MOD, moderate; COVID-19, Coronavirus Disease 2019.

*Percentage is calculated on total number of vaccinated patients as indicated appropriately in each column.

**Percentage is calculated on total number of prescribed mAbs and antivirals as indicated appropriately in each column.